Literature DB >> 26473473

Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.

Elizabeth D Bacci1, Dorota Staniewska1, Karin S Coyne1, Stacey Boyer2, Leigh Ann White2, Neta Zach3, Jesse M Cedarbaum2.   

Abstract

Our objective was to examine dimensionality and item-level performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) across time using classical and modern test theory approaches. Confirmatory factor analysis (CFA) and Item Response Theory (IRT) analyses were conducted using data from patients with amyotrophic lateral sclerosis (ALS) Pooled Resources Open-Access ALS Clinical Trials (PRO-ACT) database with complete ALSFRS-R data (n = 888) at three time-points (Time 0, Time 1 (6-months), Time 2 (1-year)). Results demonstrated that in this population of 888 patients, mean age was 54.6 years, 64.4% were male, and 93.7% were Caucasian. The CFA supported a 4* individual-domain structure (bulbar, gross motor, fine motor, and respiratory domains). IRT analysis within each domain revealed misfitting items and overlapping item response category thresholds at all time-points, particularly in the gross motor and respiratory domain items. Results indicate that many of the items of the ALSFRS-R may sub-optimally distinguish among varying levels of disability assessed by each domain, particularly in patients with less severe disability. Measure performance improved across time as patient disability severity increased. In conclusion, modifications to select ALSFRS-R items may improve the instrument's specificity to disability level and sensitivity to treatment effects.

Entities:  

Keywords:  Amyotrophic Lateral Sclerosis Functional Rating Scale; disability; item response theory; psychometric assessment

Mesh:

Year:  2015        PMID: 26473473     DOI: 10.3109/21678421.2015.1095930

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  14 in total

1.  Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.

Authors:  Leigh E Colvin; Zachariah W Foster; Thor D Stein; Manisha Thakore-James; Mohammad Kian Salajegheh; Kendall Carr; Keith R Spencer; Nazifa Abdul Rauf; Latease Adams; James G Averill; Sean E Walker; Ian Robey; Victor E Alvarez; Bertrand R Huber; Ann C McKee; Neil W Kowall; Christopher B Brady
Journal:  Muscle Nerve       Date:  2022-06-04       Impact factor: 3.852

2.  Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes.

Authors:  Jue Wang; Sheng Luo
Journal:  Stat Med       Date:  2017-06-01       Impact factor: 2.373

3.  An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients.

Authors:  Dongwoo Chae; Kyungsoo Park
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-24       Impact factor: 2.745

4.  Joint modeling of multiple repeated measures and survival data using multidimensional latent trait linear mixed model.

Authors:  Jue Wang; Sheng Luo
Journal:  Stat Methods Med Res       Date:  2018-10-11       Impact factor: 3.021

5.  Communicative Participation in People with Amyotrophic Lateral Sclerosis.

Authors:  Malin Sixt Börjesson; Lena Hartelius; Katja Laakso
Journal:  Folia Phoniatr Logop       Date:  2020-01-09       Impact factor: 0.849

6.  Evaluating person-centered factors associated with brain-computer interface access to a commercial augmentative and alternative communication paradigm.

Authors:  Kevin M Pitt; Jonathan S Brumberg
Journal:  Assist Technol       Date:  2021-03-05

7.  Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

Authors:  Leonhard A Bakker; Carin D Schröder; Michael A van Es; Paul Westers; Johanna M A Visser-Meily; Leonard H van den Berg
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

8.  Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Marinus J C Eijkemans; Toby A Ferguson; Stavros Nikolakopoulos; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-30       Impact factor: 10.154

9.  Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.

Authors:  Jin-Mo Park; Sun-Young Kim; Donghwi Park; Jin-Sung Park
Journal:  Neurol Sci       Date:  2019-08-30       Impact factor: 3.307

10.  Amyotrophic lateral sclerosis care in Saudi Arabia: A survey of providers' perceptions.

Authors:  Ahmad R Abuzinadah; Aysha A AlShareef; Abdullah AlKutbi; Ahmed K Bamaga; Ali Alshehri; Hussein Algahtani; Edward Cupler; Mohammed H Alanazy
Journal:  Brain Behav       Date:  2020-08-15       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.